On Jan. 2, 2025, an international study led by researchers at Karolinska Institutet in Sweden shows that AI-based…
On Oct. 4, 2024, researchers from Oxford university announced they had been awarded funding from Cancer Research UK…
On Sept. 18, 2024, researchers from the Wellcome Sanger Institute and their collaborators reported that they had identified…
On Mar. 18, 2024, the U.S. Environmental Protection Agency (EPA) announced a final rule to prohibit ongoing uses…
On Aug. 31, 2023, the U.S. Food and Drug Administration (FDA) cleared for marketing the updated 23andMe Personal…
On Nov. 16, 2022, the Cancer Prevention and Research Institute of Texas (CPRIT) approved $12 million in recruitment…
On Jun. 21, 2022, Anixa Biosciences announced the publication of a peer-reviewed journal article in Clinical and Experimental…
On Nov. 4, 2020, McGill University Professor William Foulkes awarded 2020 Wilder-Penfield Prize for research in the genetics…
On Apr. 6, 2020, the National Cancer Institute awarded of $14.54 million to Roswell Park Comprehensive Cancer Center…
On Jan. 22, 2019, GlaxoSmithKline acquired TESARO based in Waltham, Massachusetts, for an aggregate cash consideration of approximately…
On Jan. 18, 2019 Masonic Cancer Center researchers received $1.4 million in grants for ovarian cancer research from…
On Mar. 6, 2018, the U.S. Food and Drug Administration authorized 23andMe’s Personal Genome Service Genetic Health Risk…
On May 8, 2013, was the first World Ovarian Cancer Day. On this day, ovarian cancer organizations from…
On Oct. 16, 2006, the Cancer Genome Atlas program, created by National Cancer Institute and the National Human…
On Jul. 17, 2006, Eli Lilly and Company’s Gemzar was approved for use in the treatment of women…
On Jul. 17, 2002, A National Cancer Institute funded trial showed that postmenopausal women who used estrogen replacement…
On Feb. 7, 2002, scientists from the National Cancer Institute (NCI) and the Food and Drug Administration (FDA)…
On Jun. 14, 1996, topotecan (Hycamptin), the first of a class of drugs that interferes with the enzyme…
On Oct. 7, 1994, a strong candidate for the 17q-linked BRCA1 gene, which influences susceptibility to breast and…
In 1994, Mary-Claire King, PhD, a University of Washington professor of genome sciences and medicine, discovered the “breast…
In 1993, the Washington University School of Medicine announced that it was a participating site for the prostate,…
In 1993, the Prostate, Lung, Colorectal, and Ovarian trial was launched The trial was designed to determine whether…
On Dec. 18, 1992, Taxol (paclitaxel), an anticancer drug extracted from the bark of the Pacific yew, received…
On Mar. 3, 1989, the U.S. Food and Drug Administration (FDA) approved Bristol-Myers’ PARAPLATIN (carboplatin) for the treatment…
In 1989, carboplatin, a drug related to cisplatin, was approved by the FDA for initial treatment of advanced…
On Dec. 19, 1978, the U.S. Food and Drug Administration approved Cisplatin for use in testicular and ovarian…
In 1978, the U.S. Food and Drug Administration (FDA) approved cisplatin (Platinol) for use in combination with other…
In 1970, Cisplatin, a platinum-containing anticancer compound with unique biologic effects, entered clinical trials. On Dec. 19, 1978,…
In 1967, E.R. Squibb & Sons delved into cancer research, discovering and developing hydroxyurea for leukemia and advanced…